Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 9800 Mount Pyramid Court, Suite 400 ENGLEWOOD CO 80112 |
Tel: | N/A |
Website: | https://ampiopharma.com |
IR: | See website |
Key People | ||
Michael A. Martino Chief Executive Officer, Director | Daniel G. Stokely Chief Financial Officer, Secretary |
Business Overview |
Ampio Pharmaceuticals, Inc. is a drug discovery and development company. The Company is focused on combining scientific, clinical, and manufacturing capabilities to develop therapies aimed at treating conditions for which limited treatment options exist. |
Financial Overview |
For the fiscal year ended 31 December 2023, Ampio Pharmaceuticals Inc revenues was not reported. Net loss decreased 47% to $8.6M. Lower net loss reflects General and administrative - Balancing v decrease of 37% to $5.8M (expense), Research and development - Balancing val decrease of 60% to $2M (expense), Labor & Related Expenses in R&D decrease of 88% to $332K (expense). |
Employees: | 6 as of Feb 1, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$9.40M as of Dec 31, 2023 |
Net annual income (TTM): | -$8.63M as of Dec 31, 2023 |
Free cash flow (TTM): | -$8.56M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 1,135,358 as of Mar 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |